WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs) for cancer immunotherapy, and Cognate BioServices, a contract development and manufacturing organization (CDMO) in the global cellular therapies industry, have entered an agreement to expand WindMIL’s clinical manufacturing capacity.
 
“Our clinical program with MILs, including our ongoing Phase 2a trial in non-small-cell lung cancer (NSCLC), is growing rapidly,” said Don Hayden, chairman and chief executive officer, WindMIL. “We look forward to expanding our collaboration with the Cognate team to ensure we are well-positioned to provide MILs products to patients in our current and future clinical studies.”
 
The initial contract between the two companies enabled the successful completion of tech transfer and the start of clinical manufacturing in 2019. The expanded agreement will substantially increase WindMIL’s clinical manufacturing footprint at Cognate.
 
J. Kelly Ganjei, chief executive officer, Cognate BioServices, said, “We are extremely happy to be able to provide expanded manufacturing capacity to WindMIL. WindMIL and Cognate share the same patient-focused mindset and dedication to producing products of the highest quality for patients with currently unmet medical needs. We look forward to expanding the partnership between our two organizations.”